Adamas Pharmaceuticals Inc (NASDAQ:ADMS) CEO Gregory T. Went sold 6,319 shares of the firm’s stock in a transaction dated Wednesday, March 20th. The shares were sold at an average price of $7.99, for a total transaction of $50,488.81. Following the completion of the transaction, the chief executive officer now directly owns 176,291 shares in the company, valued at $1,408,565.09. The sale was disclosed in a document filed with the SEC, which is available at this link.

ADMS traded down $0.02 during trading on Thursday, reaching $7.99. The company’s stock had a trading volume of 257,527 shares, compared to its average volume of 883,228. The company has a debt-to-equity ratio of 1.31, a current ratio of 9.41 and a quick ratio of 9.20. Adamas Pharmaceuticals Inc has a 1 year low of $7.42 and a 1 year high of $32.90. The firm has a market capitalization of $219.87 million, a price-to-earnings ratio of -1.64 and a beta of 1.49.

Adamas Pharmaceuticals (NASDAQ:ADMS) last announced its quarterly earnings results on Monday, March 4th. The specialty pharmaceutical company reported ($1.06) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($1.36) by $0.30. The business had revenue of $13.32 million during the quarter, compared to the consensus estimate of $13.30 million. Adamas Pharmaceuticals had a negative net margin of 384.77% and a negative return on equity of 101.46%. On average, equities analysts anticipate that Adamas Pharmaceuticals Inc will post -4.14 earnings per share for the current fiscal year.

A number of brokerages recently weighed in on ADMS. Needham & Company LLC lowered shares of Adamas Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, March 5th. Cowen lowered shares of Adamas Pharmaceuticals from an “outperform” rating to a “market perform” rating and decreased their price target for the company from $30.00 to $15.00 in a research note on Tuesday, March 5th. Mizuho lowered shares of Adamas Pharmaceuticals from a “neutral” rating to an “underperform” rating and decreased their target price for the stock from $11.00 to $5.00 in a research note on Tuesday, March 5th. BidaskClub raised shares of Adamas Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Monday, February 25th. Finally, Zacks Investment Research lowered shares of Adamas Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, February 27th. Two research analysts have rated the stock with a sell rating, five have given a hold rating and four have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $23.88.

Institutional investors have recently bought and sold shares of the stock. Bank of New York Mellon Corp lifted its holdings in Adamas Pharmaceuticals by 12.7% in the 2nd quarter. Bank of New York Mellon Corp now owns 246,352 shares of the specialty pharmaceutical company’s stock worth $6,363,000 after buying an additional 27,696 shares during the period. First Trust Advisors LP purchased a new stake in Adamas Pharmaceuticals in the 3rd quarter worth approximately $1,698,000. American Century Companies Inc. lifted its holdings in Adamas Pharmaceuticals by 26.8% in the 3rd quarter. American Century Companies Inc. now owns 125,213 shares of the specialty pharmaceutical company’s stock worth $2,507,000 after buying an additional 26,503 shares during the period. Alliancebernstein L.P. lifted its holdings in Adamas Pharmaceuticals by 18.1% in the 3rd quarter. Alliancebernstein L.P. now owns 846,379 shares of the specialty pharmaceutical company’s stock worth $16,945,000 after buying an additional 129,763 shares during the period. Finally, AXA lifted its holdings in Adamas Pharmaceuticals by 2.2% in the 3rd quarter. AXA now owns 190,830 shares of the specialty pharmaceutical company’s stock worth $3,820,000 after buying an additional 4,037 shares during the period. Hedge funds and other institutional investors own 88.28% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This piece of content was originally posted by Daily Political and is the sole property of of Daily Political. If you are viewing this piece of content on another domain, it was stolen and reposted in violation of U.S. & international copyright & trademark laws. The correct version of this piece of content can be accessed at https://www.dailypolitical.com/2019/03/21/adamas-pharmaceuticals-inc-adms-ceo-sells-50488-81-in-stock.html.

Adamas Pharmaceuticals Company Profile

Adamas Pharmaceuticals, Inc discovers, develops, and sells therapies for chronic neurologic disorders. The company's approved/commercial product is GOCOVRI, an amantadine therapy for the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease. Its partnered approved/commercial products include Namzaric (memantine hydrochloride extended-release and donepezil hydrochloride) capsules; and Namenda XR (memantine hydrochloride) extended release capsules for the treatment of moderate to severe Alzheimer's disease.

Featured Article: Can systematic risk be avoided?

Insider Buying and Selling by Quarter for Adamas Pharmaceuticals (NASDAQ:ADMS)

Receive News & Ratings for Adamas Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.